Quanterix Unveils Dual Biomarker Blood Test for Personalized Multiple Sclerosis Monitoring
Quanterix Corporation has published a clinical study in the journal Brain, validating a dual biomarker blood test for monitoring multiple sclerosis (MS). The study shows that Simoa assays for GFAP and NfL can predict relapse and chronic disability progression in MS patients. A free online tool is available for clinicians to assess biomarker status using age, sex, and BMI, supporting personalized MS management.
Quanterix Corporation has announced the publication of a landmark clinical study in the journal Brain, validating a dual biomarker blood test approach for monitoring multiple sclerosis (MS). The study demonstrates that multiplexed Simoa assays for Glial Fibrillary Acidic Protein (GFAP) and Neurofilament Light Chain (NfL) provide complementary insights for predicting relapse and chronic disability progression in MS patients. The results, which have already been published, leverage Simoa technology and an extensive normative data infrastructure to enable personalized interpretation of individual patient results. A free online tool is available to assist clinicians in assessing biomarker status using age, sex, and BMI, supporting a precision medicine approach to MS management. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quanterix Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20251117284338) on November 17, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
